InvestorsHub Logo
Followers 839
Posts 120657
Boards Moderated 13
Alias Born 09/05/2002

Re: db7 post# 6672

Monday, 11/13/2023 6:23:28 PM

Monday, November 13, 2023 6:23:28 PM

Post# of 6750
Lowering HBsAg is the easy part. The question is whether patients who stop treatment will relapse and need to go back on drug; if these patients relapse, then the triple-drug regimen of Imdusiran (AB-729), VTP-300, and a nucleoside is no better than a nucleoside alone.

In other words, it’s too soon to say whether the 3-drug regimen discussed in the ABUS/BRNS* joint PR has any merit.

*f/k/a VACC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News